RecruitingPhase 4

Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone

United States132 participantsStarted 2025-01-13

Plain-language summary

This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone

Who can participate

Age range45 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Cataract diagnosis: clinically significant age-related cataract eligible for phacoemulsification in the study eye. * OAG or OHT diagnosis: either OAG (i.e. primary, pseudoexfoliation, or pigmentary glaucoma) or OHT in the study eye (i.e., eye to undergo cataract surgery) Exclusion Criteria: * Active corneal inflammation or edema. * Retinal disorders not associated with glaucoma.

What they're measuring

Change from baseline in mean diurnal IOP

Timeframe: 3 Months

Trial details

NCT IDNCT06848946

SponsorGlaukos Corporation

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-08

Contact for this trial

Study Manager

949-739-8749 ClinicalResearch@glaukos.com

View on ClinicalTrials.gov More Glaucoma, Open-angle trials